From discovery to delivery: making therapies reach patients faster

David W Miller, CEO of Genesis Research Group, discusses how pharma's decade-long development approach is no longer fit for purpose.

Related Posts

“No magic wand” for Novo Nordisk, as CagriSema pen supp...

Nov 23, 2024

Be Bio’s haemophilia B treatment gains FDA orphan drug ...

Jun 6, 2024

Vast sequencing project begins to unlock human genome’s...

Apr 27, 2023